- Companies
- Allarity Therapeutics
Allarity Therapeutics Valuation Multiples
Allarity Therapeutics is valued at $14M as of November 2026, a 0.5x revenue multiple. In the last 12 months, Allarity Therapeutics revenue was $37M.
Allarity Therapeutics Overview
About Allarity Therapeutics
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
Founded
2021
HQ
Employees
7
Website
Sectors
Financials (LTM)
EV
$20M
Valuation Multiples
Start free trialAllarity Therapeutics Financials
Allarity Therapeutics reported last 12-month revenue of $37M.
In the same LTM period, Allarity Therapeutics generated $37M in gross profit and had net loss of ($12M).
Allarity Therapeutics P&L
In the most recent fiscal year, Allarity Therapeutics reported revenue of $320K and EBITDA of ($12M).
Allarity Therapeutics is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (3702%), and net margin of (3510%).
Financial data powered by Morningstar, Inc.
Allarity Therapeutics Stock Performance
Allarity Therapeutics has current market cap of $14M, and enterprise value of $20M.
Market Cap Evolution
Allarity Therapeutics' stock price is $0.90.
Allarity Therapeutics has an EPS (earnings per share) of $-0.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20M | $14M | 6.6% | - | - | - | $-0.70 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAllarity Therapeutics Valuation Multiples
Allarity Therapeutics trades at 0.5x EV/Revenue multiple, and (1.7x) EV/EBITDA.
Allarity Therapeutics Financial Valuation Multiples
As of November 19, 2026, Allarity Therapeutics has market cap of $14M and EV of $20M.
Allarity Therapeutics has a P/E ratio of (1.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Allarity Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Allarity Therapeutics Margins & Growth Rates
Allarity Therapeutics decreased revenue by 91% but net profit grew by 8% in the last fiscal year.
In the most recent fiscal year, Allarity Therapeutics reported gross margin of 100%, EBITDA margin of (3702%), and net margin of (3510%).
Allarity Therapeutics Margins
Allarity Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Allarity Therapeutics Operational KPIs
Allarity Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.8M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Allarity Therapeutics Competitors
Allarity Therapeutics competitors include Abera Bioscience, Türk İlaç, Celyad Oncology, Marker Therapeutics, Fractyl Health, Seres Therapeutics, Hepion Pharmaceuticals, Biophytis, Diamyd Medical and Acumen Pharmaceuticals.
Most Allarity Therapeutics public comparables operate across Biopharmaceuticals and BioTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | ($1M) | - | - | (12.3x) | - | |||
| $90M | $22M | 1.1x | - | 4.6x | - | |||
| $23K | ($1M) | 618.3x | - | (10.6x) | - | |||
| - | ($13M) | - | 1.3x | (0.4x) | (0.5x) | |||
| - | ($141M) | - | - | (0.3x) | (0.6x) | |||
| $789K | ($62M) | 41.5x | 4.5x | (0.5x) | - | |||
| - | ($8M) | - | - | (1.7x) | - | |||
| - | ($10M) | - | 103.2x | (2.1x) | (0.8x) | |||
This data is available for Pro users. Sign up to see all Allarity Therapeutics competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Allarity Therapeutics
| When was Allarity Therapeutics founded? | Allarity Therapeutics was founded in 2021. |
| Where is Allarity Therapeutics headquartered? | Allarity Therapeutics is headquartered in United States. |
| How many employees does Allarity Therapeutics have? | As of today, Allarity Therapeutics has over 7 employees. |
| Is Allarity Therapeutics publicly listed? | Yes, Allarity Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Allarity Therapeutics? | Allarity Therapeutics trades under ALLR ticker. |
| When did Allarity Therapeutics go public? | Allarity Therapeutics went public in 2021. |
| Who are competitors of Allarity Therapeutics? | Allarity Therapeutics main competitors include Abera Bioscience, Türk İlaç, Celyad Oncology, Marker Therapeutics, Fractyl Health, Seres Therapeutics, Hepion Pharmaceuticals, Biophytis, Diamyd Medical, Acumen Pharmaceuticals. |
| What is the current market cap of Allarity Therapeutics? | Allarity Therapeutics' current market cap is $14M. |
| What is the current revenue of Allarity Therapeutics? | Allarity Therapeutics' last 12 months revenue is $37M. |
| What is the current revenue growth of Allarity Therapeutics? | Allarity Therapeutics revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Allarity Therapeutics? | Current revenue multiple of Allarity Therapeutics is 0.5x. |
| Is Allarity Therapeutics profitable? | No, Allarity Therapeutics is not profitable. |
| What is the current net income of Allarity Therapeutics? | Allarity Therapeutics' last 12 months net income is ($12M). |
| How many companies Allarity Therapeutics has acquired to date? | Allarity Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Allarity Therapeutics has invested to date? | Allarity Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Allarity Therapeutics
Lists including Allarity Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




